Platelet amyloid precursor protein forms in AD: A peripheral diagnostic tool and a pharmacological target

Alessandro Padovani, Barbara Borroni, Francesca Colciaghi, Lucia Pastorino, Silvana Archetti, Elisabetta Cottini, Luigi Caimi, Flaminio Cattabeni, Monica Di Luca

Research output: Contribution to journalArticlepeer-review


Alzheimer Disease (AD) is characterized by the progressive deposition of β-amyloid in the parenchyma and cerebral microvasculature. The β-amyloid peptide derives from the metabolism of a larger precursor, Amyloid Precursor Protein (APP). This protein is present in central nervous system, but it is also expressed in peripheral tissues such as circulating cells. An alteration of the APP forms pattern in platelets has been recently reported in AD patients when compared to platelets both of control subjects or non AD patients (NADD). The accuracy of the assay to identify AD is high and decreased levels are found throughout the course of AD with a significant association with severity of symptoms. Moreover, a recent study has demonstrated that AD patients on donepezil (5 mg daily) for 4 weeks displayed two-fold increase in their APPr baseline levels up to normal range. Thus, platelet APP ratio (APPr) holds the potential to be a clinical marker, which might be of helpful and adjunctive value in the diagnosis of AD and in tracking the course of illness, also in the early stages when pharmacological treatment has the greatest potential of being effective.

Original languageEnglish
Pages (from-to)1997-2004
Number of pages8
JournalMechanisms of Ageing and Development
Issue number16
Publication statusPublished - 2001


  • Alzheimer
  • Amyloid precursor protein
  • Biomarker
  • Platelets

ASJC Scopus subject areas

  • Ageing
  • Biochemistry
  • Developmental Biology
  • Developmental Neuroscience


Dive into the research topics of 'Platelet amyloid precursor protein forms in AD: A peripheral diagnostic tool and a pharmacological target'. Together they form a unique fingerprint.

Cite this